RU2017140065A - Композиции нуклеиновой кислоты-катионного полимера и способы их получения и применения - Google Patents
Композиции нуклеиновой кислоты-катионного полимера и способы их получения и применения Download PDFInfo
- Publication number
- RU2017140065A RU2017140065A RU2017140065A RU2017140065A RU2017140065A RU 2017140065 A RU2017140065 A RU 2017140065A RU 2017140065 A RU2017140065 A RU 2017140065A RU 2017140065 A RU2017140065 A RU 2017140065A RU 2017140065 A RU2017140065 A RU 2017140065A
- Authority
- RU
- Russia
- Prior art keywords
- carbohydrate
- nucleic acid
- poly
- cationic polymer
- composition according
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 53
- 238000000034 method Methods 0.000 title claims 52
- 229920000642 polymer Polymers 0.000 title claims 5
- 150000001720 carbohydrates Chemical class 0.000 claims 63
- 235000014633 carbohydrates Nutrition 0.000 claims 61
- 108020004707 nucleic acids Proteins 0.000 claims 44
- 102000039446 nucleic acids Human genes 0.000 claims 44
- 150000007523 nucleic acids Chemical class 0.000 claims 44
- 229920006317 cationic polymer Polymers 0.000 claims 43
- 229920002873 Polyethylenimine Polymers 0.000 claims 14
- 102000006601 Thymidine Kinase Human genes 0.000 claims 13
- 108020004440 Thymidine kinase Proteins 0.000 claims 13
- -1 aziridinyl cytosine Chemical compound 0.000 claims 12
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims 11
- 208000009889 Herpes Simplex Diseases 0.000 claims 10
- 229920000729 poly(L-lysine) polymer Polymers 0.000 claims 10
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 claims 9
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 8
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 claims 8
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 8
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Natural products NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 8
- 239000003623 enhancer Substances 0.000 claims 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N lysine Chemical compound NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 8
- 229920001542 oligosaccharide Polymers 0.000 claims 8
- 150000002482 oligosaccharides Chemical class 0.000 claims 8
- 239000013612 plasmid Substances 0.000 claims 8
- 125000000647 trehalose group Chemical group 0.000 claims 8
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-Glutamic acid Natural products OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 7
- 229940104302 cytosine Drugs 0.000 claims 7
- 229960002989 glutamic acid Drugs 0.000 claims 7
- 229960004275 glycolic acid Drugs 0.000 claims 7
- 108090000623 proteins and genes Proteins 0.000 claims 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 6
- OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 claims 6
- 108020004414 DNA Proteins 0.000 claims 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 6
- 239000004472 Lysine Substances 0.000 claims 6
- 229930006000 Sucrose Natural products 0.000 claims 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 6
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 6
- 229920001577 copolymer Polymers 0.000 claims 6
- 239000008103 glucose Substances 0.000 claims 6
- 150000004676 glycans Chemical class 0.000 claims 6
- 150000002772 monosaccharides Chemical group 0.000 claims 6
- 239000002105 nanoparticle Substances 0.000 claims 6
- 229960003104 ornithine Drugs 0.000 claims 6
- 229920001282 polysaccharide Polymers 0.000 claims 6
- 239000005017 polysaccharide Substances 0.000 claims 6
- 230000001105 regulatory effect Effects 0.000 claims 6
- 239000005720 sucrose Substances 0.000 claims 6
- 201000006082 Chickenpox Diseases 0.000 claims 5
- 102000009016 Cholera Toxin Human genes 0.000 claims 5
- 108010049048 Cholera Toxin Proteins 0.000 claims 5
- 206010046980 Varicella Diseases 0.000 claims 5
- HPZMWTNATZPBIH-UHFFFAOYSA-N 1-methyladenine Chemical compound CN1C=NC2=NC=NC2=C1N HPZMWTNATZPBIH-UHFFFAOYSA-N 0.000 claims 4
- RFLVMTUMFYRZCB-UHFFFAOYSA-N 1-methylguanine Chemical compound O=C1N(C)C(N)=NC2=C1N=CN2 RFLVMTUMFYRZCB-UHFFFAOYSA-N 0.000 claims 4
- FZWGECJQACGGTI-UHFFFAOYSA-N 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 claims 4
- XMSMHKMPBNTBOD-UHFFFAOYSA-N 2-dimethylamino-6-hydroxypurine Chemical compound N1C(N(C)C)=NC(=O)C2=C1N=CN2 XMSMHKMPBNTBOD-UHFFFAOYSA-N 0.000 claims 4
- SMADWRYCYBUIKH-UHFFFAOYSA-N 2-methyl-7h-purin-6-amine Chemical compound CC1=NC(N)=C2NC=NC2=N1 SMADWRYCYBUIKH-UHFFFAOYSA-N 0.000 claims 4
- OIVLITBTBDPEFK-UHFFFAOYSA-N 5,6-dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 claims 4
- OQRXBXNATIHDQO-UHFFFAOYSA-N 6-chloropyridine-3,4-diamine Chemical compound NC1=CN=C(Cl)C=C1N OQRXBXNATIHDQO-UHFFFAOYSA-N 0.000 claims 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 4
- 102100026189 Beta-galactosidase Human genes 0.000 claims 4
- 101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 claims 4
- 102000000496 Carboxypeptidases A Human genes 0.000 claims 4
- 108010080937 Carboxypeptidases A Proteins 0.000 claims 4
- 101150090188 Cdk8 gene Proteins 0.000 claims 4
- 108010058546 Cyclin D1 Proteins 0.000 claims 4
- 102000003909 Cyclin E Human genes 0.000 claims 4
- 108090000257 Cyclin E Proteins 0.000 claims 4
- 102000000311 Cytosine Deaminase Human genes 0.000 claims 4
- 108010080611 Cytosine Deaminase Proteins 0.000 claims 4
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims 4
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims 4
- 101150029707 ERBB2 gene Proteins 0.000 claims 4
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 claims 4
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 claims 4
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims 4
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims 4
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 4
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 4
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims 4
- 101710101148 Probable 6-oxopurine nucleoside phosphorylase Proteins 0.000 claims 4
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 claims 4
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 claims 4
- 241000589516 Pseudomonas Species 0.000 claims 4
- 102000030764 Purine-nucleoside phosphorylase Human genes 0.000 claims 4
- 101710132082 Pyrimidine/purine nucleoside phosphorylase Proteins 0.000 claims 4
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims 4
- 108700025701 Retinoblastoma Genes Proteins 0.000 claims 4
- 108010039491 Ricin Proteins 0.000 claims 4
- 101150112625 SSN3 gene Proteins 0.000 claims 4
- 101100150415 Schizosaccharomyces pombe (strain 972 / ATCC 24843) srb10 gene Proteins 0.000 claims 4
- 102000013537 Thymidine Phosphorylase Human genes 0.000 claims 4
- 102100023132 Transcription factor Jun Human genes 0.000 claims 4
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims 4
- 125000003277 amino group Chemical group 0.000 claims 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims 4
- 108010005774 beta-Galactosidase Proteins 0.000 claims 4
- 230000015572 biosynthetic process Effects 0.000 claims 4
- 101150073031 cdk2 gene Proteins 0.000 claims 4
- 108010079940 cyanogenic beta-glucosidase Proteins 0.000 claims 4
- 150000002016 disaccharides Chemical class 0.000 claims 4
- 108010062699 gamma-Glutamyl Hydrolase Proteins 0.000 claims 4
- 229960002885 histidine Drugs 0.000 claims 4
- 239000008101 lactose Substances 0.000 claims 4
- 150000004702 methyl esters Chemical class 0.000 claims 4
- 231100000590 oncogenic Toxicity 0.000 claims 4
- 230000002246 oncogenic effect Effects 0.000 claims 4
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical group O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims 4
- 229960004441 tyrosine Drugs 0.000 claims 4
- 102000002554 Cyclin A Human genes 0.000 claims 3
- 108010068192 Cyclin A Proteins 0.000 claims 3
- 102000016607 Diphtheria Toxin Human genes 0.000 claims 3
- 108010053187 Diphtheria Toxin Proteins 0.000 claims 3
- 239000000463 material Substances 0.000 claims 3
- 229940035893 uracil Drugs 0.000 claims 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 2
- SATCOUWSAZBIJO-UHFFFAOYSA-N 1-methyladenine Natural products N=C1N(C)C=NC2=C1NC=N2 SATCOUWSAZBIJO-UHFFFAOYSA-N 0.000 claims 2
- WJNGQIYEQLPJMN-IOSLPCCCSA-N 1-methylinosine Chemical compound C1=NC=2C(=O)N(C)C=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WJNGQIYEQLPJMN-IOSLPCCCSA-N 0.000 claims 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims 2
- HLYBTPMYFWWNJN-UHFFFAOYSA-N 2-(2,4-dioxo-1h-pyrimidin-5-yl)-2-hydroxyacetic acid Chemical compound OC(=O)C(O)C1=CNC(=O)NC1=O HLYBTPMYFWWNJN-UHFFFAOYSA-N 0.000 claims 2
- YSAJFXWTVFGPAX-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetic acid Chemical compound OC(=O)COC1=CNC(=O)NC1=O YSAJFXWTVFGPAX-UHFFFAOYSA-N 0.000 claims 2
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 claims 2
- GJAKJCICANKRFD-UHFFFAOYSA-N 4-acetyl-4-amino-1,3-dihydropyrimidin-2-one Chemical compound CC(=O)C1(N)NC(=O)NC=C1 GJAKJCICANKRFD-UHFFFAOYSA-N 0.000 claims 2
- LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 claims 2
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 2
- DCPSTSVLRXOYGS-UHFFFAOYSA-N 6-amino-1h-pyrimidine-2-thione Chemical compound NC1=CC=NC(S)=N1 DCPSTSVLRXOYGS-UHFFFAOYSA-N 0.000 claims 2
- CKOMXBHMKXXTNW-UHFFFAOYSA-N 6-methyladenine Chemical compound CNC1=NC=NC2=C1N=CN2 CKOMXBHMKXXTNW-UHFFFAOYSA-N 0.000 claims 2
- SOTIPZUHKSPAMN-IOSLPCCCSA-N 9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-methyl-3h-purin-6-one Chemical compound C12=NC(C)=NC(O)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O SOTIPZUHKSPAMN-IOSLPCCCSA-N 0.000 claims 2
- SWJYOKZMYFJUOY-KQYNXXCUSA-N 9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-(methylamino)-7h-purin-8-one Chemical compound OC1=NC=2C(NC)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O SWJYOKZMYFJUOY-KQYNXXCUSA-N 0.000 claims 2
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 claims 2
- 102000053642 Catalytic RNA Human genes 0.000 claims 2
- 108090000994 Catalytic RNA Proteins 0.000 claims 2
- 108091026890 Coding region Proteins 0.000 claims 2
- 108010020076 Cytochrome P-450 CYP2B1 Proteins 0.000 claims 2
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 claims 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 2
- 229930182847 D-glutamic acid Natural products 0.000 claims 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 2
- 108090000204 Dipeptidase 1 Proteins 0.000 claims 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 2
- 229930091371 Fructose Natural products 0.000 claims 2
- 239000005715 Fructose Substances 0.000 claims 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 2
- 229920002527 Glycogen Polymers 0.000 claims 2
- 229930010555 Inosine Natural products 0.000 claims 2
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims 2
- 229930064664 L-arginine Natural products 0.000 claims 2
- 235000014852 L-arginine Nutrition 0.000 claims 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 2
- 229920002774 Maltodextrin Polymers 0.000 claims 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims 2
- 229930195725 Mannitol Natural products 0.000 claims 2
- SGSSKEDGVONRGC-UHFFFAOYSA-N N(2)-methylguanine Chemical compound O=C1NC(NC)=NC2=C1N=CN2 SGSSKEDGVONRGC-UHFFFAOYSA-N 0.000 claims 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 2
- 102000004459 Nitroreductase Human genes 0.000 claims 2
- 108091034117 Oligonucleotide Proteins 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 2
- 108091027967 Small hairpin RNA Proteins 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims 2
- 229920002472 Starch Polymers 0.000 claims 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 2
- 102100033220 Xanthine oxidase Human genes 0.000 claims 2
- 108010093894 Xanthine oxidase Proteins 0.000 claims 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims 2
- 102000006635 beta-lactamase Human genes 0.000 claims 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims 2
- 239000001913 cellulose Substances 0.000 claims 2
- 229920002678 cellulose Polymers 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000008121 dextrose Substances 0.000 claims 2
- 125000000600 disaccharide group Chemical group 0.000 claims 2
- 229960002949 fluorouracil Drugs 0.000 claims 2
- 238000004108 freeze drying Methods 0.000 claims 2
- 125000000524 functional group Chemical group 0.000 claims 2
- 229930182830 galactose Natural products 0.000 claims 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 2
- 229940096919 glycogen Drugs 0.000 claims 2
- 229960003786 inosine Drugs 0.000 claims 2
- 239000000594 mannitol Substances 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- 108020001162 nitroreductase Proteins 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- 229920000724 poly(L-arginine) polymer Polymers 0.000 claims 2
- 229920000083 poly(allylamine) Polymers 0.000 claims 2
- 229920001308 poly(aminoacid) Polymers 0.000 claims 2
- 229920002643 polyglutamic acid Polymers 0.000 claims 2
- 108010055896 polyornithine Proteins 0.000 claims 2
- 229920002717 polyvinylpyridine Polymers 0.000 claims 2
- 235000018102 proteins Nutrition 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108091092562 ribozyme Proteins 0.000 claims 2
- 239000004055 small Interfering RNA Substances 0.000 claims 2
- 239000000600 sorbitol Substances 0.000 claims 2
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims 2
- 239000008107 starch Substances 0.000 claims 2
- 235000019698 starch Nutrition 0.000 claims 2
- 150000004043 trisaccharides Chemical class 0.000 claims 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 2
- MQJSSLBGAQJNER-UHFFFAOYSA-N 5-(methylaminomethyl)-1h-pyrimidine-2,4-dione Chemical compound CNCC1=CNC(=O)NC1=O MQJSSLBGAQJNER-UHFFFAOYSA-N 0.000 claims 1
- KELXHQACBIUYSE-UHFFFAOYSA-N 5-methoxy-1h-pyrimidine-2,4-dione Chemical compound COC1=CNC(=O)NC1=O KELXHQACBIUYSE-UHFFFAOYSA-N 0.000 claims 1
- ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 claims 1
- BYPCVKNBGDKXLB-UHFFFAOYSA-N 6-(aminomethyl)-5-methyl-1h-pyrimidine-2,4-dione Chemical compound CC1=C(CN)NC(=O)NC1=O BYPCVKNBGDKXLB-UHFFFAOYSA-N 0.000 claims 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims 1
- 102000016736 Cyclin Human genes 0.000 claims 1
- 108050006400 Cyclin Proteins 0.000 claims 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 1
- 229930182816 L-glutamine Natural products 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims 1
- 230000002759 chromosomal effect Effects 0.000 claims 1
- 206010013023 diphtheria Diseases 0.000 claims 1
- 108060006633 protein kinase Proteins 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
- 229950000329 thiouracil Drugs 0.000 claims 1
- 229940104230 thymidine Drugs 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0091—Purification or manufacturing processes for gene therapy compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Dermatology (AREA)
- Manufacturing & Machinery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL23864315 | 2015-05-05 | ||
| IL238643 | 2015-05-05 | ||
| PCT/IL2016/050477 WO2016178233A1 (en) | 2015-05-05 | 2016-05-05 | Nucleic acid-cationic polymer compositions and methods of making and using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2017140065A true RU2017140065A (ru) | 2019-06-05 |
| RU2017140065A3 RU2017140065A3 (enExample) | 2019-09-27 |
Family
ID=56134418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017140065A RU2017140065A (ru) | 2015-05-05 | 2016-05-05 | Композиции нуклеиновой кислоты-катионного полимера и способы их получения и применения |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20180154023A1 (enExample) |
| EP (1) | EP3291799A1 (enExample) |
| JP (2) | JP2018515479A (enExample) |
| KR (1) | KR20180015145A (enExample) |
| CN (1) | CN107735079A (enExample) |
| AU (1) | AU2016258326A1 (enExample) |
| BR (1) | BR112017023788A2 (enExample) |
| CA (1) | CA2984879A1 (enExample) |
| IL (1) | IL255254A0 (enExample) |
| MX (1) | MX2017014060A (enExample) |
| PH (1) | PH12017502216A1 (enExample) |
| RU (1) | RU2017140065A (enExample) |
| SG (2) | SG11201708760PA (enExample) |
| WO (1) | WO2016178233A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018515479A (ja) * | 2015-05-05 | 2018-06-14 | イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブライ ユニバーシティー オブ エルサレム リミテッドＹｉｓｓｕｍ Ｒｅｓｅａｒｃｈ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏｍｐａｎｙ Ｏｆ Ｔｈｅ Ｈｅｂｒｅｗ Ｕｎｉｖｅｒｓｔｙ Ｏｆ Ｊｅｒｕｓａｌｅｍ Ｌｔｄ． | 核酸−カチオン性ポリマー組成物、並びにその作製方法及び使用方法 |
| DE102017003004A1 (de) | 2017-03-23 | 2018-09-27 | Friedrich-Schiller-Universität Jena | Kationische Polymere mit D-Fructose-Substituenten |
| US10849921B2 (en) * | 2017-05-17 | 2020-12-01 | Bioncotech Therapeutics Sl | Pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine |
| EP3924463A1 (en) | 2019-02-11 | 2021-12-22 | Excellgene SA | Novel eukaryotic cell transfection systems and related methods |
| CN111363761A (zh) * | 2020-03-17 | 2020-07-03 | 苏州吉恒基因科技有限公司 | 利用阳离子多聚体dna复合物促进aav介导的基因表达方法 |
| CA3181339A1 (en) * | 2020-04-27 | 2021-11-04 | Juno Therapeutics, Inc. | Stabilization of polyethyleneimine-deoxyribonucleic acid complex size and activity |
| TW202228727A (zh) * | 2020-10-01 | 2022-08-01 | 德商拜恩迪克公司 | 適用於治療之微脂體ｒｎａ調配物之製備及儲存 |
| WO2022249180A1 (en) | 2021-05-25 | 2022-12-01 | Ramot At Tel-Aviv University Ltd. | Compositions comprising extracellular vesicles and an active agent and uses thereof |
| CN113501889A (zh) * | 2021-07-06 | 2021-10-15 | 郑州大学 | 一种三七多糖阳离子衍生物的制备方法及其应用 |
| CN116549626A (zh) * | 2022-01-27 | 2023-08-08 | 深圳瑞吉生物科技有限公司 | 一种载核酸脂质纳米颗粒冻干制剂及其制备方法与应用 |
| CN114762731B (zh) * | 2022-05-16 | 2024-08-23 | 常州大学 | 一种延长基因药物在温和条件下储存时间的方法 |
| CN116036043A (zh) * | 2023-01-10 | 2023-05-02 | 深圳市乐土生物医药有限公司 | 一种核酸药物制剂、冻干粉及制备方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| FR2722506B1 (fr) | 1994-07-13 | 1996-08-14 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucleiques, preparation et utilisations |
| US6087164A (en) * | 1997-10-03 | 2000-07-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods and compositions for inducing tumor-specific cytotoxicity |
| US20040142474A1 (en) * | 2000-09-14 | 2004-07-22 | Expression Genetics, Inc. | Novel cationic lipopolymer as a biocompatible gene delivery agent |
| WO2007007317A1 (en) | 2005-07-07 | 2007-01-18 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Nucleic acid agents for downregulating h19, and methods of using same |
| JP2009508516A (ja) | 2005-09-22 | 2009-03-05 | イッサム リサーチ ディベロプメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム | 核酸構築物、薬剤組成物、及び癌治療のためのその使用方法 |
| CA2675967A1 (en) | 2007-01-16 | 2008-07-24 | Yissum Research Development Company Of The Hebrew University Of Jerusale M | Nucleic acid constructs and methods for specific silencing of h19 |
| US20090042825A1 (en) * | 2007-08-06 | 2009-02-12 | Majed Matar | Composition, method of preparation & application of concentrated formulations of condensed nucleic acids with a cationic lipopolymer |
| CN101820864A (zh) * | 2007-08-06 | 2010-09-01 | 艾根股份有限公司 | 核酸-脂聚合物组合物 |
| BRPI0818937B8 (pt) | 2007-10-25 | 2021-05-25 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | constructos contendo múltiplos cassetes de expressão para terapia de câncer |
| WO2010028093A2 (en) * | 2008-09-03 | 2010-03-11 | Senesco Technologies, Inc. | Use of a truncated elf-5a1 polynucleotide to induce apoptosis in cancer cells |
| DE102009006606A1 (de) * | 2009-01-29 | 2010-08-05 | Philipps-Universität Marburg | Nicht-virales Transfektionsmittel |
| JP2018515479A (ja) * | 2015-05-05 | 2018-06-14 | イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブライ ユニバーシティー オブ エルサレム リミテッドＹｉｓｓｕｍ Ｒｅｓｅａｒｃｈ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏｍｐａｎｙ Ｏｆ Ｔｈｅ Ｈｅｂｒｅｗ Ｕｎｉｖｅｒｓｔｙ Ｏｆ Ｊｅｒｕｓａｌｅｍ Ｌｔｄ． | 核酸−カチオン性ポリマー組成物、並びにその作製方法及び使用方法 |
-
2016
- 2016-05-05 JP JP2017556986A patent/JP2018515479A/ja active Pending
- 2016-05-05 KR KR1020177034664A patent/KR20180015145A/ko not_active Ceased
- 2016-05-05 CN CN201680039770.4A patent/CN107735079A/zh active Pending
- 2016-05-05 RU RU2017140065A patent/RU2017140065A/ru not_active Application Discontinuation
- 2016-05-05 BR BR112017023788A patent/BR112017023788A2/pt not_active Application Discontinuation
- 2016-05-05 CA CA2984879A patent/CA2984879A1/en not_active Abandoned
- 2016-05-05 WO PCT/IL2016/050477 patent/WO2016178233A1/en not_active Ceased
- 2016-05-05 MX MX2017014060A patent/MX2017014060A/es unknown
- 2016-05-05 US US15/571,699 patent/US20180154023A1/en not_active Abandoned
- 2016-05-05 AU AU2016258326A patent/AU2016258326A1/en not_active Abandoned
- 2016-05-05 EP EP16730012.8A patent/EP3291799A1/en not_active Withdrawn
- 2016-05-05 SG SG11201708760PA patent/SG11201708760PA/en unknown
- 2016-05-05 SG SG10201909209R patent/SG10201909209RA/en unknown
-
2017
- 2017-10-25 IL IL255254A patent/IL255254A0/en unknown
- 2017-12-05 PH PH12017502216A patent/PH12017502216A1/en unknown
-
2020
- 2020-01-02 US US16/732,770 patent/US20200138977A1/en not_active Abandoned
-
2021
- 2021-05-07 JP JP2021079039A patent/JP2021130671A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL255254A0 (en) | 2017-12-31 |
| EP3291799A1 (en) | 2018-03-14 |
| US20200138977A1 (en) | 2020-05-07 |
| US20180154023A1 (en) | 2018-06-07 |
| BR112017023788A2 (pt) | 2018-10-16 |
| KR20180015145A (ko) | 2018-02-12 |
| CN107735079A (zh) | 2018-02-23 |
| MX2017014060A (es) | 2018-07-06 |
| CA2984879A1 (en) | 2016-11-10 |
| JP2021130671A (ja) | 2021-09-09 |
| AU2016258326A1 (en) | 2017-11-23 |
| WO2016178233A1 (en) | 2016-11-10 |
| RU2017140065A3 (enExample) | 2019-09-27 |
| SG11201708760PA (en) | 2017-11-29 |
| PH12017502216A1 (en) | 2018-06-11 |
| JP2018515479A (ja) | 2018-06-14 |
| SG10201909209RA (en) | 2019-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230190667A1 (en) | Methods of preparing polyelectrolyte complex nanoparticles | |
| Lai et al. | Nucleic acid delivery with chitosan and its derivatives | |
| US9895451B2 (en) | Formulations for targeted release of agents to low pH tissue environments or cellular compartments and methods of use thereof | |
| Wu et al. | Bioinspired artificial tobacco mosaic virus with combined oncolytic properties to completely destroy multidrug‐resistant cancer | |
| CN107001627B (zh) | 用于将核酸引入细胞的组合物 | |
| JP2018515479A5 (enExample) | ||
| US11007279B2 (en) | Highly stable biodegradable gene vector platforms for overcoming biological barriers | |
| US10465042B2 (en) | Poly(amine-co-ester) nanoparticles and methods of use thereof | |
| JP2021130671A (ja) | 核酸−カチオン性ポリマー組成物、並びにその作製方法及び使用方法 | |
| US12558429B2 (en) | Poly(amine-co-ester) polymers with modified end groups and enhanced pulmonary delivery | |
| US11814464B2 (en) | Poly(amine-co-ester) polymers and polyplexes with modified end groups and methods of use thereof | |
| WO2014066898A9 (en) | A layer-by-layer approach to co-deliver dna and sirna via aunps: a potential platform for modifying release kinetics | |
| US10682422B2 (en) | Formulations for targeted release of agents under low pH conditions and methods of use thereof | |
| WO2017197128A1 (en) | Poly(amine-co-ester) nanoparticles and methods of use thereof | |
| WO2016081621A1 (en) | Formulations for targeted release of agents under low ph conditions and methods of use thereof | |
| Akbari et al. | β-Cyclodextrins-based nano carriers for cancer therapy | |
| US20140294909A1 (en) | Nanocomposites of gold and polymers | |
| US20210024694A1 (en) | Polymer compound for nucleic acid delivery | |
| US20250017866A1 (en) | Polymers and nanoparticles for intramuscular nucleic acid delivery | |
| Panghal et al. | Suicide gene therapy: A promising approach towards gene delivery | |
| Genç et al. | Labeling MCF-7 Cell Line with Interleukin-6/Calcium Phosphate Nanoparticles. | |
| US20240279651A1 (en) | Nucleic acid nanoparticles, pharmaceutical compositions, and methods of use thereof | |
| HK40077723A (en) | Methods of preparing polyelectrolyte complex nanoparticles | |
| HK1247839A1 (en) | Nucleic acid-cationic polymer compositions and methods of making and using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20200123 |